These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 31085742

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Clinical effectiveness and cost-effectiveness of use of therapeutic monitoring of tumour necrosis factor alpha (TNF-α) inhibitors [LISA-TRACKER® enzyme-linked immunosorbent assay (ELISA) kits, TNF-α-Blocker ELISA kits and Promonitor® ELISA kits] versus standard care in patients with Crohn's disease: systematic reviews and economic modelling.
    Freeman K, Connock M, Auguste P, Taylor-Phillips S, Mistry H, Shyangdan D, Court R, Arasaradnam R, Sutcliffe P, Clarke A.
    Health Technol Assess; 2016 Nov; 20(83):1-288. PubMed ID: 27845027
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Development of an ELISA-Based Competitive Binding Assay for the Analysis of Drug Concentration and Antidrug Antibody Levels in Patients Receiving Adalimumab or Infliximab.
    Hock BD, Stamp LK, Hayman MW, Keating PE, Helms ET, Barclay ML.
    Ther Drug Monit; 2016 Feb; 38(1):32-41. PubMed ID: 26222874
    [Abstract] [Full Text] [Related]

  • 8. Therapeutic drug monitoring of infliximab: performance evaluation of three commercial ELISA kits.
    Schmitz EM, van de Kerkhof D, Hamann D, van Dongen JL, Kuijper PH, Brunsveld L, Scharnhorst V, Broeren MA.
    Clin Chem Lab Med; 2016 Jul 01; 54(7):1211-9. PubMed ID: 26587745
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Comparative Evaluation of Four Commercially Available Immunoassays for Therapeutic Drug Monitoring of Infliximab and Adalimumab.
    Rissel F, Cazaubon Y, Saffar S, Altwegg R, Artasone M, Lozano C, Vincent T, Jentzer A.
    Int J Mol Sci; 2023 Jun 20; 24(12):. PubMed ID: 37373525
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Comparative study of a point-of-care test and an enzyme-linked immunosorbent assay (ELISA) for infliximab levels.
    Thunberg J, Grännö O, Bergemalm D, Eriksson C, Visuri I, Eberhardson M, Halfvarson J.
    Scand J Gastroenterol; 2024 Jun 20; 59(2):150-155. PubMed ID: 37882356
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Analytical and clinical performance evaluation of two POC tests for therapeutic drug monitoring of infliximab.
    Van den Bossche D, De Smet D, Debrabandere J, Vanpoucke H.
    Clin Chem Lab Med; 2019 May 27; 57(6):856-863. PubMed ID: 30838834
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.